SK Biopharm to Raise At Least 5 tln Won in IPO

SEOUL, Nov. 25 (Korea Bizwire) — South Korean drug firm SK Biopharmaceuticals Co. is expected to raise at least 5 trillion won (US$4.25 billion) through a planned share sale, analysts said Monday. The company said Friday that XCOPRI, or cenobamate, has won approval from the U.S. Food and Drug Administration (FDA) for the treatment of [...]